我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

绵阳市1882例慢性心力衰竭住院患者药物治疗动态分析(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2006年第3期
页码:
306-308
栏目:
临床研究
出版日期:
2006-06-25

文章信息/Info

Title:
Analysis of medication for 1882 chronic heart failure in City of Mianyang
作者:
蒋涛1; 李德才1; 刘思泰1; 唐焕君1; 李健2; 凌云3
1．绵阳市404医院；2.绵阳市中心医院心内科；3.绵阳市人民医院心内科，四川 绵阳 621000
Author(s):
JIANG Tao;  LI De-cai;  LIU Si-tai;  TANG Huan-jun;  LI Jian;  LING Yun
Department of Cardiology, Mianyang 404 Hospital, Mianyang ，Sichuan 621000, China
关键词:
心力衰竭; 慢性; 药物治疗
Keywords:
heart failure;  chronic;  drug therapy
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的 了解绵阳市1882例慢性心力衰竭患者药物治疗动态，初步分析用药合理性。方法 采用1998、2001和2004年住院慢性心力衰竭患者病历数据库,对1882例慢性心力衰竭患者使用药物治疗状况进行调查分析。结果 1882例患者在1998、2001和2004年药物使用率分别是:利尿剂63.7%→68.1%→74.5 %、洋地黄类40.2%→42.4%→67.9%、血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂（ACEI/ARB）18.2%→30.3%→57.1%、β受体阻滞剂（β-blocker）14.9%→31.2%→60.1%、硝酸盐类42.5%→48.2%→56.3%、非洋地黄类正性肌力药物25.7%→28.9%→20.7%、钙离子拮抗剂17.5%→18.3%→20.1%。不使用βblocker的主要原因是窦性心动过缓。不使用ACEI/ ARB 的主要原因是低血压。未考虑使用βblocker占不用原因的32.6%， 未考虑使用ACEI/ARB占不用原因的34.6%。结论 提示自心力衰竭治疗指南公布以来，慢性心力衰竭规范化药物治疗水平有了明显提高。
Abstract:
AIM To make a detailed survey of the medicine used for chronic heart failure (CHF) in Mianyang City. METHODS By utilizing the medical history database of 1882 patients of three municipal hospitals in the year of 1998, 2001 and 2004, the medicine administration for the treatment of CHF patients was analyzed. RESULTS There were total of 1882 patients with CHF in the year of 1998, 2001 and 2004. In 1998, 2001 and 2004, the rate of diuretics used was respectively 63.7, 68.1 and 74.5%, the rate of digitalis was respectively 40.2%, 42.4% and 67.9%; the rate of angiotensinconverting enzyme inhibitors/angiotensin Ⅱ receptor blocker (ACEI/ARB) was respectively 18.2%, 30.3% and 57.2%, the rate of βblocker was respectively 14.9%, 31.2%, 60.1%, the rate of nitrate was respectively 42.5%, 48.2% and 70.3%, the rate of nondigitalis positive inotropic drugs was respectively 25.7%, 28.9% and 14.7% and the rate of calcium channel blocker (CCB) was respectively 17.5%, 18.3% and 20.1%. βblocker was not used for the patients with sinus bradycardia and ACEI/ARB was not used for the patients with hypotension. About 32.6% of those who did not using βblocker gave no consideration of using it in the first place and 34.6% was true of those in the case of not using ACEI/ARB. CONCLUSION The overall medicine administration for CHF in the City of Mianyang has been markedly improved since the issue of therapy guidance for CHF.

参考文献/References

［1］ Task force for the diagnosis and treatment of chronic heart failure,European society of Cardiology,Remme WJ,et al. Guidelines for the diagnosis and treatment of chronic heart failure［J］. Eur Heart J, 2001, 22(17):1527 -1560.

［2］Hunt SA,Baker DEW,Chin MH,et al. ACC/ AHA Guidelines for the evaluation and management of chronic heart failure in the adult ［J］. Circulation, 2001， 104(24):2996-3007.

［3］中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 慢性收缩性心力衰竭治疗建议［J］. 中华心血管病杂志, 2002， 30（1）: 7-23.

［4］中华医学会心血管病学分会. 中国部分地区1980 、1990 、2000 年慢性心力衰竭住院病例回顾性调查［J］. 中华心血管病杂志, 2002，30（8）:450-455.

［5］ Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial［J］. J Card Fail, 1995, 1(5):371-380.

［6］CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure. result of the north scandinavian enalapril survival Study (CONSENSUS)［J］. N Engl J Med， 1987,316（23）:1429-1435.

［7］CIBIS2 Ⅱ Investigators and Committees. The cardiac insufficiency bisoprolol Study Ⅱ (CIBIS2 Ⅱ) : a randomized trial［J］. Lancet， 1999， 353(9146):9-13.

［8］MERITHF study group. Effect of metoprolol CR/XL in chronic heart failure：metoprolol CR/XL randomized intervention trial in congestive heart failure (MERITHF)［J］. Lancet,1999,353(9169):2001-2007.

［9］Fowler MB. Carvedilol prospective randomized cumulative survival (COPERNICUS) Trial : carvedilol in severe heart failure［J］. Am J Cardiol，2004，93(9A) :35B-39B.

备注/Memo

备注/Memo:
收稿日期：2005-10-13.作者简介：蒋涛，副主任医师，硕士 Tel：（0816）2330089 Email：jiangt404@sohu.com
更新日期/Last Update: